TABLE 2: Participants who experienced an improvement in clinical status at day 28, defined by a decrease greater or equal to two points on the World Health Organization’s seven-category ordinal scale for clinical improvement.

	N	%	Total	Relative risk (CI 95%)
Ixekizumab	13	81.3	16	1.00 (0.72 - 1.39)
Low-dose IL-2	9	64.3	14	0.79 (0.50 - 1.25)
Colchicine	14	100.0	14	1.23 (0.97 - 1.55)
SOC	13	81.3	16	1
Total	49	81.7	60	-

SOC: Standard of care; IL-2: interleukin 2. p-value Fisher's exact test: 0.101; CI: confidence interval.